Ribonucleotide reductase expression in cervical cancer

A Radiation Therapy Oncology Group translational science analysis

Charles A. Kunos, Kathryn Winter, Adam P. Dicker, William Small, Fadi W. Abdul-Karim, Dawn Dawson, Anuja Jhingran, Richard K Valicenti, Joanne B. Weidhaas, David K. Gaffney

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. Methods/Materials: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (nodepositive stages IA-IVA) received weekly cisplatin (40 mg/m2) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (nodepositive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m2) on days 1, 23, and 43 and 5-FU (1 g/m2 for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. Results: Fifty-one tissue sampleswere analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95%confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). Conclusions: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.

Original languageEnglish (US)
Pages (from-to)615-621
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume23
Issue number4
DOIs
StatePublished - May 2013

Fingerprint

Ribonucleotide Reductases
Radiation Oncology
Uterine Cervical Neoplasms
Radiotherapy
Disease-Free Survival
Celecoxib
Brachytherapy
Cisplatin
Confidence Intervals
Amifostine
Radiation
Chemoradiotherapy
Proportional Hazards Models
Fluorouracil
Biomarkers
Immunohistochemistry
Clinical Trials
Phenotype
Recurrence

Keywords

  • Cervical cancer
  • Radiosensitivity
  • Ribonucleotide reductase

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Ribonucleotide reductase expression in cervical cancer : A Radiation Therapy Oncology Group translational science analysis. / Kunos, Charles A.; Winter, Kathryn; Dicker, Adam P.; Small, William; Abdul-Karim, Fadi W.; Dawson, Dawn; Jhingran, Anuja; Valicenti, Richard K; Weidhaas, Joanne B.; Gaffney, David K.

In: International Journal of Gynecological Cancer, Vol. 23, No. 4, 05.2013, p. 615-621.

Research output: Contribution to journalArticle

Kunos, CA, Winter, K, Dicker, AP, Small, W, Abdul-Karim, FW, Dawson, D, Jhingran, A, Valicenti, RK, Weidhaas, JB & Gaffney, DK 2013, 'Ribonucleotide reductase expression in cervical cancer: A Radiation Therapy Oncology Group translational science analysis', International Journal of Gynecological Cancer, vol. 23, no. 4, pp. 615-621. https://doi.org/10.1097/IGC.0b013e31828b4eb5
Kunos, Charles A. ; Winter, Kathryn ; Dicker, Adam P. ; Small, William ; Abdul-Karim, Fadi W. ; Dawson, Dawn ; Jhingran, Anuja ; Valicenti, Richard K ; Weidhaas, Joanne B. ; Gaffney, David K. / Ribonucleotide reductase expression in cervical cancer : A Radiation Therapy Oncology Group translational science analysis. In: International Journal of Gynecological Cancer. 2013 ; Vol. 23, No. 4. pp. 615-621.
@article{8e07db0c0289483f82cd715052e914dc,
title = "Ribonucleotide reductase expression in cervical cancer: A Radiation Therapy Oncology Group translational science analysis",
abstract = "Objective: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. Methods/Materials: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (nodepositive stages IA-IVA) received weekly cisplatin (40 mg/m2) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (nodepositive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m2) on days 1, 23, and 43 and 5-FU (1 g/m2 for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. Results: Fifty-one tissue sampleswere analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2{\%}, 80{\%}, and 47{\%}, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95{\%}confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95{\%} confidence interval, 2.2-13.8; P = 0.0003). Conclusions: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.",
keywords = "Cervical cancer, Radiosensitivity, Ribonucleotide reductase",
author = "Kunos, {Charles A.} and Kathryn Winter and Dicker, {Adam P.} and William Small and Abdul-Karim, {Fadi W.} and Dawn Dawson and Anuja Jhingran and Valicenti, {Richard K} and Weidhaas, {Joanne B.} and Gaffney, {David K.}",
year = "2013",
month = "5",
doi = "10.1097/IGC.0b013e31828b4eb5",
language = "English (US)",
volume = "23",
pages = "615--621",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Ribonucleotide reductase expression in cervical cancer

T2 - A Radiation Therapy Oncology Group translational science analysis

AU - Kunos, Charles A.

AU - Winter, Kathryn

AU - Dicker, Adam P.

AU - Small, William

AU - Abdul-Karim, Fadi W.

AU - Dawson, Dawn

AU - Jhingran, Anuja

AU - Valicenti, Richard K

AU - Weidhaas, Joanne B.

AU - Gaffney, David K.

PY - 2013/5

Y1 - 2013/5

N2 - Objective: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. Methods/Materials: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (nodepositive stages IA-IVA) received weekly cisplatin (40 mg/m2) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (nodepositive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m2) on days 1, 23, and 43 and 5-FU (1 g/m2 for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. Results: Fifty-one tissue sampleswere analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95%confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). Conclusions: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.

AB - Objective: To evaluate pretherapy ribonucleotide reductase (RNR) expression and its effect on radiochemotherapeutic outcome in women with cervical cancer. Methods/Materials: Pretherapy RNR M1, M2, and M2b immunohistochemistry was done on cervical cancer specimens retrieved from women treated on Radiation Therapy Oncology Group (RTOG) 0116 and 0128 clinical trials. Enrollees of RTOG 0116 (nodepositive stages IA-IVA) received weekly cisplatin (40 mg/m2) with amifostine (500 mg) and extended-field radiation then brachytherapy (85 Gy). Enrollees of RTOG 0128 (nodepositive or bulky ≥5 cm, stages IB-IIA or stages IIB-IVA) received cisplatin (75 mg/m2) on days 1, 23, and 43 and 5-FU (1 g/m2 for 4 days) during pelvic radiation then brachytherapy (85 Gy), plus celecoxib (400 mg twice daily, day 1 through 1 year). Disease-free survival (DFS) was estimated univariately by the Kaplan-Meier method. Cox proportional hazards models evaluated the impact of RNR immunoreactivity on DFS. Results: Fifty-one tissue sampleswere analyzed: 13 from RTOG 0116 and 38 from RTOG 0128. M1, M2, and M2b overexpression (3+) frequencies were 2%, 80%, and 47%, respectively. Low-level (0-1+, n = 44/51) expression of the regulatory subunit M1 did not associate with DFS (P = 0.38). High (3+) M2 expression occurred in most (n = 41/51) but without impact alone on DFS (hazard ratio, 0.54; 95%confidence interval, 0.2-1.4; P = 0.20). After adjusting for M2b status, pelvic node-positive women had increased hazard for relapse or death (hazard ratio, 5.5; 95% confidence interval, 2.2-13.8; P = 0.0003). Conclusions: These results suggest that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome. Future RNR biomarker studies are warranted.

KW - Cervical cancer

KW - Radiosensitivity

KW - Ribonucleotide reductase

UR - http://www.scopus.com/inward/record.url?scp=84879912271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879912271&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e31828b4eb5

DO - 10.1097/IGC.0b013e31828b4eb5

M3 - Article

VL - 23

SP - 615

EP - 621

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -